비교리스트

 카트 문의
시장보고서
상품코드
1563910

세계의 소 호흡기 질환 치료제 시장

Bovine Respiratory Disease Treatment
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 179 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

소 호흡기 질환 치료제 세계 시장 규모는 2030년까지 34억 달러에 달할 것으로 예상

2023년 22억 달러로 추정되는 소 호흡기 질환 치료제 세계 시장은 2023-2030년의 분석 기간 동안 연평균 6.4% 성장하여 2030년에는 34억 달러에 달할 것으로 예상됩니다. 본 보고서에서 분석한 부문 중 하나인 백신은 CAGR 7.8%를 기록하여 분석 기간 종료 시점에 14억 달러에 이를 것으로 예상됩니다. 항생제 분야의 성장률은 분석 기간 동안 CAGR 6.5%로 추정됩니다.

미국 시장은 5억 7,810만 달러로 추정, 중국은 CAGR 9.7%로 성장할 것으로 예상

미국의 소 호흡기 질환 치료 시장은 2023년 5억 7,810만 달러로 추정됩니다. 세계 2위의 경제 대국인 중국은 2023-2030년 9.7%의 연평균 복합 성장률(CAGR)로 2030년까지 8억 8,100만 달러 규모에 도달할 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 3.1%와 5.8%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 유럽에서는 독일이 3.9%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다.

세계 소 호흡기 질환 치료제 시장 - 주요 동향 및 촉진요인 정리

소 호흡기 질환이란 무엇인가?

소 호흡기 질환(Bovine Respiratory Disease: BRD)은 전 세계 소, 특히 육우와 젖소에게 영향을 미치는 심각한 건강 문제입니다. 최근에 수송된 소에게 자주 발생하기 때문에 '수송열'이라고 불리지만, 그 영향은 훨씬 더 광범위하며 모든 연령과 유형의 소에게 영향을 미칩니다. 이 질병은 복잡하고 다인자적인 병태로 운송, 혼혈, 환경 변화 등 다양한 스트레스 요인과 바이러스, 박테리아, 마이코플라즈마 등 감염 요인의 상호 작용에 의해 발생하며, BRD는 체중 증가 감소, 사료 요구량 증가, 폐사율 증가, 치료 및 예방 조치 비용으로 인해 심각한 경제적 손실을 초래하는 것으로 유명합니다. 손실을 유발하는 것으로 유명합니다. 또한 동물 복지에도 큰 영향을 미치기 때문에 보다 효과적이고 인도적인 치료법에 대한 요구가 증가하고 있으며, BRD는 복잡하고 다면적이기 때문에 그 치료는 수의학 및 가축 관리의 중요한 초점이 되고 있습니다.

소 호흡기 질환의 현재 치료 전략은 어떻게 진화하고 있는가?

지난 몇 년동안 소 호흡기 질환의 치료에 큰 진전이 있었습니다. 질병에 대한 병리학적 이해가 깊어지고 새로운 치료법이 개발되었기 때문입니다. 기존의 치료 전략은 열과 통증을 억제하는 항염증제와 같은 지지 요법과 함께 질병의 세균 성분을 표적으로 하는 광범위 항생제를 사용하는 것이 일반적이었습니다. 그러나 항생제 내성 및 이러한 치료법의 효과에 대한 우려로 인해 보다 표적화된 접근법이 모색되고 있습니다. 새로운 치료법은 진단 도구를 사용하여 특정 BRD 사례에 관여하는 특정 병원체를 식별하고 보다 맞춤화된 치료 프로토콜을 가능하게 하는 정밀의료에 점점 더 초점을 맞추었습니다. 또한, 동물의 면역 반응을 강화하여 감염을 보다 효과적으로 퇴치하는 것을 목표로 하는 면역 조절 요법에 대한 관심도 증가하고 있습니다. 이러한 발전은 회복률을 향상시킬 뿐만 아니라 항생제 과다 사용으로 인한 위험을 줄일 수 있는 보다 지속 가능하고 효과적인 치료 요법으로의 전환을 의미합니다.

소 호흡기 질환 예방의 새로운 동향은 무엇인가?

소 호흡기 질환의 예방은 중요한 분야가 되었으며, 업계에서는 발병 후 치료하는 것보다 예방하는 것이 비용 효율적이고 유익한 것으로 인식되고 있습니다. 백신 접종 프로그램은 BRD 예방의 기초이며, 가장 흔한 바이러스 및 세균성 병원체를 표적으로 하는 백신을 사용할 수 있습니다. 보다 효과적인 백신의 개발은 비강 스프레이와 같은 새로운 투여 방법을 포함하여 업계에서 진행중인 추세입니다. 또 다른 중요한 트렌드는 데이터 분석, 센서 및 모니터링 시스템을 활용하여 위험에 처한 가축을 조기에 식별하고 질병이 확산되기 전에 예방 조치를 취할 수 있는 정밀 축산 기술의 활용입니다. 이러한 기술을 통해 가축군을 지속적으로 모니터링하고 조기 개입을 통해 BRD 발생을 크게 줄일 수 있습니다. 또한, 운송 중 스트레스 감소, 영양 최적화, 적절한 사육 환경 확보 등 전반적인 가축 관리의 개선이 강조되고 있으며, 이 모든 것이 질병 발생 위험을 낮추는 데 기여하고 있습니다.

소 호흡기 질환 치료 시장의 성장 촉진요인은 무엇인가?

소 호흡기 질환 치료 시장의 성장은 기술 발전, 최종 용도의 변화, 소비자 행동의 진화와 직접적으로 관련된 몇 가지 요인에 의해 주도되고 있습니다. 주요 촉진요인 중 하나는 동물 의료 분야에서 정밀의료의 채택이 증가함에 따라 보다 정확하고 효과적인 치료가 가능해져 회복률 향상과 사망률 감소로 이어지고 있다는 점입니다. 가축 사육두수 증가와 함께 효과적인 BRD 치료 옵션에 대한 수요가 증가함에 따라 특히 신흥국 시장에서 축산업이 확대되고 있는 것도 시장 성장을 견인하고 있습니다. 또한, 인도적이고 지속 가능한 조건에서 생산된 육류 및 유제품에 대한 소비자 수요가 증가함에 따라 축산 업체들은 BRD와 같은 질병에 대해 보다 효과적이고 윤리적인 치료 프로토콜을 채택하도록 요구받고 있습니다. 또한, 가축에 대한 항생제 사용 감소에 대한 규제 압력으로 인해 면역 조절 요법이나 표적 항균제 치료와 같은 대체 치료법의 개발 및 채택이 가속화되고 있습니다. 마지막으로, 진단 기술의 발전으로 수의사가 BRD를 신속하고 정확하게 진단할 수 있게 되어 보다 신속하고 효과적인 치료가 가능해짐에 따라 시장 확대가 더욱 가속화되고 있습니다.

조사 대상 기업 예시(주목할 만한 12개 기업)

  • Bayer AG
  • Bimeda Group
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Elanco
  • Merck & Co.
  • Vetoquinol S.A.
  • Virbac Group
  • Zoetis Services LLC

    목차

    제1장 조사 방법

    제2장 주요 요약

    • 시장 개요
    • 주요 기업
    • 시장 동향과 촉진요인
    • 세계 시장 전망

    제3장 시장 분석

    • 미국
    • 캐나다
    • 일본
    • 중국
    • 유럽
    • 프랑스
    • 독일
    • 이탈리아
    • 영국
    • 스페인
    • 러시아
    • 기타 유럽
    • 아시아태평양
    • 호주
    • 인도
    • 한국
    • 기타 아시아태평양
    • 라틴아메리카
    • 아르헨티나
    • 브라질
    • 멕시코
    • 기타 라틴아메리카
    • 중동
    • 이란
    • 이스라엘
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 기타 중동
    • 아프리카

    제4장 경쟁

    LSH 24.10.07

    Global Bovine Respiratory Disease Treatment Market to Reach US$3.4 Billion by 2030

    The global market for Bovine Respiratory Disease Treatment estimated at US$2.2 Billion in the year 2023, is expected to reach US$3.4 Billion by 2030, growing at a CAGR of 6.4% over the analysis period 2023-2030. Vaccines, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Antibiotics segment is estimated at 6.5% CAGR over the analysis period.

    The U.S. Market is Estimated at US$578.1 Million While China is Forecast to Grow at 9.7% CAGR

    The Bovine Respiratory Disease Treatment market in the U.S. is estimated at US$578.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$808.1 Million by the year 2030 trailing a CAGR of 9.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

    Global Bovine Respiratory Disease Treatment Market - Key Trends and Drivers Summarized

    What Is Bovine Respiratory Disease and Why Is It a Major Concern?

    Bovine Respiratory Disease (BRD) is a significant health issue affecting cattle populations worldwide, particularly in beef and dairy herds. It is often referred to as "shipping fever" because it commonly occurs in cattle that have been recently transported, but its impact is far broader, affecting all ages and types of cattle. The disease is a complex, multifactorial condition that results from the interaction of various stress factors—such as transportation, co-mingling, and environmental changes—with infectious agents including viruses, bacteria, and mycoplasma. BRD is notorious for causing severe economic losses due to decreased weight gain, higher feed conversion rates, increased mortality, and the cost of treatment and preventive measures. It also has a substantial impact on animal welfare, leading to a push for more effective and humane treatment options. The complexity and multifaceted nature of BRD make its treatment a critical focus area in veterinary medicine and livestock management.

    How Are Current Treatment Strategies Evolving for Bovine Respiratory Disease?

    In recent years, there have been significant advancements in the treatment of Bovine Respiratory Disease, driven by a better understanding of the disease's pathology and the development of new therapeutic interventions. Traditional treatment strategies have typically involved the use of broad-spectrum antibiotics to target the bacterial component of the disease, alongside supportive care such as anti-inflammatory drugs to reduce fever and pain. However, concerns about antibiotic resistance and the efficacy of such treatments have led to the exploration of more targeted approaches. Newer therapies are increasingly focused on precision medicine, which involves the use of diagnostic tools to identify the specific pathogens involved in a particular case of BRD, allowing for more tailored treatment protocols. Additionally, there has been a growing interest in immunomodulatory therapies that aim to boost the animal’s immune response to fight off the infection more effectively. These advancements represent a shift towards more sustainable and effective treatment regimens that not only improve recovery rates but also help mitigate the risks associated with antibiotic overuse.

    What Are the Emerging Trends in Bovine Respiratory Disease Prevention?

    The prevention of Bovine Respiratory Disease has become a key area of focus, as the industry recognizes that preventing the disease is more cost-effective and beneficial than treating it after it occurs. Vaccination programs are a cornerstone of BRD prevention, with vaccines available that target the most common viral and bacterial pathogens. The development of more effective vaccines, including those that can be administered through novel delivery methods such as intranasal sprays, is an ongoing trend in the industry. Another significant trend is the use of precision livestock farming techniques, which leverage data analytics, sensors, and monitoring systems to identify at-risk animals early and take preventive measures before the disease can spread. These technologies allow for the continuous monitoring of cattle herds, enabling early intervention that can significantly reduce the incidence of BRD. Additionally, there is a growing emphasis on improving overall herd management practices, such as reducing stress during transportation, optimizing nutrition, and ensuring proper housing conditions, all of which contribute to a lower risk of disease outbreaks.

    What Is Driving the Growth of the Bovine Respiratory Disease Treatment Market?

    The growth in the Bovine Respiratory Disease treatment market is driven by several factors directly related to technological advancements, changing end-use practices, and evolving consumer behavior. One of the key drivers is the increasing adoption of precision medicine in veterinary care, which allows for more accurate and effective treatments, leading to higher recovery rates and reduced mortality. The expansion of livestock farming, particularly in developing regions, is also fueling market growth, as the demand for effective BRD treatment options rises in tandem with the growth of the cattle population. Moreover, there is a growing consumer demand for meat and dairy products produced under humane and sustainable conditions, which has pushed livestock producers to adopt more effective and ethical treatment protocols for diseases like BRD. Regulatory pressures to reduce antibiotic use in livestock have also accelerated the development and adoption of alternative treatment methods, such as immunomodulatory therapies and targeted antimicrobial therapies. Finally, advancements in diagnostic technologies are making it easier for veterinarians to quickly and accurately diagnose BRD, leading to more timely and effective treatments, further driving the market's expansion.

    Select Competitors (Total 12 Featured) -

    • Bayer AG
    • Bimeda Group
    • Boehringer Ingelheim International GmbH
    • Ceva Sante Animale
    • Elanco
    • Merck & Co., Inc.
    • Vetoquinol S.A.
    • Virbac Group
    • Zoetis Services LLC

    TABLE OF CONTENTS

    I. METHODOLOGY

    II. EXECUTIVE SUMMARY

    • 1. MARKET OVERVIEW
      • Influencer Market Insights
      • World Market Trajectories
      • Bovine Respiratory Disease Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
      • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • 2. FOCUS ON SELECT PLAYERS
    • 3. MARKET TRENDS & DRIVERS
      • Rising Incidence of Respiratory Infections Propels Demand for Advanced Treatment Solutions
      • Increasing Focus on Animal Welfare Expands Addressable Market Opportunity for Humane Treatment Options
      • Growing Awareness of Antimicrobial Resistance Strengthens the Business Case for Non-Antibiotic Therapies
      • Innovations in Vaccination Technology Spur Growth in Preventive Care Solutions
      • Regulatory Pressures on Antibiotic Use Throw the Spotlight on Alternative Therapies
      • Here's How Precision Livestock Farming Drives Adoption of Targeted Treatment Approaches
      • Expanding Global Livestock Population Accelerates Demand for Bovine Respiratory Disease Treatments
      • Increasing Integration of Digital Health Tools in Veterinary Care Generates New Market Opportunities
      • Growing Consumer Demand for Quality Meat and Dairy Products Drives Adoption of Effective Disease Management
    • 4. GLOBAL MARKET PERSPECTIVE
      • TABLE 1: World Bovine Respiratory Disease Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
      • TABLE 2: World Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 3: World Historic Review for Bovine Respiratory Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 4: World 16-Year Perspective for Bovine Respiratory Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
      • TABLE 5: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 6: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 7: World 16-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
      • TABLE 8: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 9: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 10: World 16-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
      • TABLE 11: World Recent Past, Current & Future Analysis for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 12: World Historic Review for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 13: World 16-Year Perspective for NSAIDs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
      • TABLE 14: World Recent Past, Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 15: World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 16: World 16-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

    III. MARKET ANALYSIS

    • UNITED STATES
      • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
      • TABLE 17: USA Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 18: USA Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 19: USA 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • CANADA
      • TABLE 20: Canada Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 21: Canada Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 22: Canada 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • JAPAN
      • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
      • TABLE 23: Japan Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 24: Japan Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 25: Japan 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • CHINA
      • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
      • TABLE 26: China Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 27: China Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 28: China 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • EUROPE
      • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
      • TABLE 29: Europe Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 30: Europe Historic Review for Bovine Respiratory Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 31: Europe 16-Year Perspective for Bovine Respiratory Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
      • TABLE 32: Europe Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 33: Europe Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 34: Europe 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • FRANCE
      • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
      • TABLE 35: France Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 36: France Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 37: France 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • GERMANY
      • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
      • TABLE 38: Germany Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 39: Germany Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 40: Germany 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • ITALY
      • TABLE 41: Italy Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 42: Italy Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 43: Italy 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • UNITED KINGDOM
      • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
      • TABLE 44: UK Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 45: UK Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 46: UK 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • SPAIN
      • TABLE 47: Spain Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 48: Spain Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 49: Spain 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • RUSSIA
      • TABLE 50: Russia Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 51: Russia Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 52: Russia 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • REST OF EUROPE
      • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 54: Rest of Europe Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 55: Rest of Europe 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • ASIA-PACIFIC
      • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
      • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 57: Asia-Pacific Historic Review for Bovine Respiratory Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 58: Asia-Pacific 16-Year Perspective for Bovine Respiratory Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
      • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 60: Asia-Pacific Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 61: Asia-Pacific 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • AUSTRALIA
      • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
      • TABLE 62: Australia Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 63: Australia Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 64: Australia 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • INDIA
      • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
      • TABLE 65: India Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 66: India Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 67: India 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • SOUTH KOREA
      • TABLE 68: South Korea Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 69: South Korea Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 70: South Korea 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • REST OF ASIA-PACIFIC
      • TABLE 71: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 72: Rest of Asia-Pacific Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 73: Rest of Asia-Pacific 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • LATIN AMERICA
      • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
      • TABLE 74: Latin America Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 75: Latin America Historic Review for Bovine Respiratory Disease Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 76: Latin America 16-Year Perspective for Bovine Respiratory Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
      • TABLE 77: Latin America Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 78: Latin America Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 79: Latin America 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • ARGENTINA
      • TABLE 80: Argentina Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 81: Argentina Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 82: Argentina 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • BRAZIL
      • TABLE 83: Brazil Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 84: Brazil Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 85: Brazil 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • MEXICO
      • TABLE 86: Mexico Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 87: Mexico Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 88: Mexico 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • REST OF LATIN AMERICA
      • TABLE 89: Rest of Latin America Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 90: Rest of Latin America Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 91: Rest of Latin America 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • MIDDLE EAST
      • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
      • TABLE 92: Middle East Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 93: Middle East Historic Review for Bovine Respiratory Disease Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 94: Middle East 16-Year Perspective for Bovine Respiratory Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
      • TABLE 95: Middle East Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 96: Middle East Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 97: Middle East 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • IRAN
      • TABLE 98: Iran Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 99: Iran Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 100: Iran 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • ISRAEL
      • TABLE 101: Israel Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 102: Israel Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 103: Israel 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • SAUDI ARABIA
      • TABLE 104: Saudi Arabia Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 105: Saudi Arabia Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 106: Saudi Arabia 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • UNITED ARAB EMIRATES
      • TABLE 107: UAE Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 108: UAE Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 109: UAE 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • REST OF MIDDLE EAST
      • TABLE 110: Rest of Middle East Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 111: Rest of Middle East Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 112: Rest of Middle East 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
    • AFRICA
      • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
      • TABLE 113: Africa Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 114: Africa Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 115: Africa 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030

    IV. COMPETITION

    • 비교리스트
    0 건의 상품을 선택 중
    상품 비교하기
    전체삭제